MEMORIAL DAY FLASH SALE: 50% OFF BENZINGA PRO
As we honor our freedom, take a stand today. Secure the financial freedom that both you and your family deserve. Get exclusive market moving news for just 50% off. Claim your 50% discount here.
- VBI Vaccines Inc (NASDAQ:VBIV) and Agenus Inc (NASDAQ:AGEN) collaborated to evaluate a combination therapy for brain cancer.
- The partnership will assess VBI-1901, VBI's cancer vaccine immunotherapeutic, and balstilimab, Agenus' monoclonal antibody targeting the programmed death receptor-1 protein, in primary glioblastoma patients as part of the adaptive platform trial, INSIGhT.
- Related: VBI Vaccines Reveals Updated Overall Survival Data From Brain Cancer Vaccine Trial.
- Under the agreement, VBI will be the study sponsor and be responsible for the operational execution of the combination trial, and Agenus will provide drug supply and scientific support.
- In the recurrent setting, VBI-1901 is in an ongoing Phase 2a study and has demonstrated encouraging tumor responses and improvement in overall survival compared to historical controls.
- One of the patients with a partial response has been on the treatment protocol for over 2.5 years with a sustained tumor response reduction of 93% relative to baseline.
- These tumor responses have translated to clinical benefit with a median overall survival rate of 12.9 months, which compares favorably to the 8-month overall survival historical control in the recurrent setting after treatment with a monotherapy.
- Price Action: VBIV shares are up 3.06% at $0.6604 on the last check Wednesday.
MEMORIAL DAY FLASH SALE: 50% OFF BENZINGA PRO
As we honor our freedom, take a stand today. Secure the financial freedom that both you and your family deserve. Get exclusive market moving news for just 50% off. Claim your 50% discount here.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!